Introduction
India has an estimated 2.4 million people living with HIV and AIDS (PLHIV); the prevalence rate is 0.31 % [1] . The epidemic, first recognized in 1986, has been stabilized largely by the concerted efforts of the Government of India (GoI), civil society, and bilateral and multilateral agencies. The burden of prevention, diagnosis and treatment has primarily been by shouldered by government and civil society organizations (CSOs) that have been active in the prevention and treatment of HIV and AIDS. The roll-out of free antiretroviral (ARV) therapy and the subsequent scaling up has been a major milestone in the success of India's AIDS control programme, enabling PLHIV to lead a prolonged and productive life. The effect of such successful prevention and treatment activities is mirrored in the reduced prevalence rates of HIV and AIDS in the country [2] . While ARV drugs are now within the reach of most PLHIV, there continues to be a burden of treatment due to hospitalization for opportunistic infections. While not all PLHIV can and will buy commercial health insurance products, the permanent exclusion 1 and pre-existing disease clauses applicable to commercial insurance prevent HIV-positive individuals from purchasing commercial insurance [3] . The view that an enabling environment should also include mainstreaming HIV in the insurance sector is gaining currency globally.
A vast amount of literature explores various health insurance options for the general population in the country [4] [5] [6] [7] . Less research exists on the issues around treatmentseeking behaviour of PLHIV and alternative modes of coverage of treatment and options in India for extending health coverage to PLHIV [8] [9] [10] . Furthermore, the two streams of literature exist in parallel, with a seeming disconnect between out-of-pocket (OOP) expenses for the general population and for HIV-positive individuals. As a result, the general discussion on insurance does not include the burden of hospitalization treatment on PLHIV or the extent to which they are able to bear the costs of such hospitalization. However, OOP expenses for accessing quality treatment, coupled with stigma and discrimination, pose major challenges for PLHIV in India. The burden is especially significant for women and children who end up at PLHIV networks after having strained a sizable proportion of their family resources for the care and treatment of an expired male member of the household [11] [12] [13] .
Other studies on the willingness in India to participate in insurance clearly highlights that individuals with substantial OOP medical expenditure would be willing to purchase actuarially fair priced health insurance products if they are aware of such products and understand their features [14] .
In India, there exists one example of a stand-alone scheme for PLHIV. In 2008, the Star Health and Allied Insurance Company launched the Star NetPlus policy for HIV-positive individuals in India. At the time of this research, the Star NetPlus Policy was offering coverage of Indian rupee (R) 30,000 at an annual premium of R1,511 to a group of 200 or more PLHIV with a CD4 count[300 cells/ mm 3 . The uptake of insurance in this scheme indicated the presence of significant demand among PLHIV for health coverage. This scheme has filled an important void and helped a number of PLHIV during their illness. However, from the viewpoint of risk and income pooling, such standalone schemes are not the most efficient way of covering population groups. From the viewpoint of commercial insurance companies, the continued exclusion of HIV in general health insurance products is based on notions that the assumed high burden of illness and treatment costs of PLHIV would adversely affect profits. Evidence now exists to show that these assumptions are no longer valid and there is no remaining reason to justify exclusion. As we discuss later, there exist other examples of schemes that are more inclusive of PLHIV, especially if they belong to the below-poverty-line (BPL) population, but countrywide national schemes operated by private as well as public sectors continue to exclude conditions related to HIV.
Over the past 2 decades, many countries have moved from a position of AIDS being excluded for risk minimization reasons to HIV being mainstreamed in health insurance. Such efforts were either in the form of legislative or regulatory measures of the state, like in the USA, South Africa and Namibia, or by the way of including HIV in existing social health insurance plans, as has happened in many Latin American countries. Around 40 countrieslargely from Africa and Central and South America-have successfully included PLHIV in health insurance coverage.
This study focuses on the possibility of HIV-positive individuals being included in mainstream insurance programmes in India and explores their willingness to pay (WTP) towards such a product. The analysis uses the contingent valuation (CV) approach, which has been increasingly used in the recent past to measure health and environmental benefits. The technique is prospective and determines WTP contingent upon a hypothetical market presented to respondents, and is essentially experimental. The main idea is to estimate the demand for a commodity for which markets do not exist. Applications to healthcare are increasing [15] [16] [17] [18] , but applications in developing countries remain few [14, 19] .
The analysis is based on a primary survey that also elicited information on illnesses and burden of treatment. The aim was to understand whether, and at what price, individuals are willing to pay for hospitalization insurance. We hope that the findings will serve as information as well as evidence in any impending policy changes on the issue of insurability of PLHIV.
Aims and Objectives
In the context of the continued exclusion of PLHIV from commercial insurance products in India, the main aim was 1 The permanent exclusion clause is for certain conditions that are excluded 'forever' from the list of benefits, irrespective of the time of its occurrence. These conditions largely represent either nonaccidental losses (i.e. the occurrence of an event could be within the control of the claimant) or poorly defined losses (i.e. time, place and cause of a loss may not be clear).
to understand if PLHIV would be willing to participate in and purchase commercial health insurance, if it were offered to them. Specifically, the survey was designed to understand the occurrence and impact of hospitalization on PLHIV; analyse their willingness to participate in commercial insurance programmes; and correlate such variation with the socioeconomic characteristics of the respondents.
Methodology

Willingness to Pay: An Overview
The basic logic behind the CV method can be described simply as follows.
The value that the respondent attaches to the good (in this case hospitalization) can be written as x i b ? e i, where x i are the regressors or the explanatory variables, b the coefficients of the regressors and e i the error term. If p i is the price at which the good is offered to individual i in the survey, then the individual will purchase the good if x i b ? e i [ p i . By randomizing price, one can calculate the probability that a randomly chosen respondent will purchase the good as a function of p i , or equivalently, the fraction of the relevant population who will purchase the good at price p i . This describes the demand curve for the good. Different distributional assumption about e i will yield different estimation techniques.
Following more recent evidence, a double-bounded model was also adopted here, in addition to open-ended questions on maximum WTP [17] . Thus, the determinants of WTP were analysed in two ways: one using open-ended questions with log of the maximum stated WTP per year as the dependent variable, and the other using a set of closedended questions. The closed-ended double-bounded questions were used in a regression using the Weibull distribution, which is useful to model data with monotone hazard rates that either decrease or increase exponentially with time (in this case, the premiums either increase or decrease depending on the responses) and is, therefore, more accurate in capturing the determinants of WTP than open-ended questions [14, 20] . The equation for both regressions can be found as appendix 1.
Sample Design and Technique
It is difficult to survey PLHIV: there are confidentiality issues; not all HIV-positive individuals know their status; those who do know may not have disclosed their status; and those who have disclosed their status may not want to be interviewed. Keeping these situations in mind, we used non-probability convenience sampling to select PLHIV for the survey. Researchers had to depend on known networks of PLHIV and include those willing to participate in the survey. The aim was to have fair representation of the insured (under the Star Health Policy, mentioned above) and uninsured PLHIV as well as all genders, including transgender PLHIV. Networks already involved with the Population Services International-Connect initiatives were accessed due to logistical reasons; the sample size was the maximum that could be interviewed within the time and resources available to the researchers. The fieldwork was conducted May to July 2011.
Operationally, the aim was to collect a sample of at least 50 respondents from each of the 15 collaborating sampling units, totalling 750 respondents. However, this target was surpassed, and the survey was administered to 1,275 respondents. Data were collected using a structured questionnaire. A copy of the instrument is provided as 'electronic supplementary material'. The questionnaire was designed to collect information on background details, housing arrangements and asset ownership, information on infection status and ARV treatment of family members. Separate sections were devoted to elicit responses on burden of illness among PLHIV in the preceding year and WTP for insurance. Even if insurance were available to PLHIV, only some would buy it; the WTP section was asked only of such respondents (987 individuals).
For the WTP section, the concept of health insurance was explained to the respondents in detail: what it entails, how it might benefit them, that potentially only hospitalization would be covered, and what paying a premium entails. The explanation stressed that insurance would not cover ARV therapy (ART) because it was available free at government-funded ART centres. Since the aim was to understand the respondents' WTP if a commercial health insurance product that included HIV was offered, the concept of insurance was explained in detail to the respondents. They were also advised that no commercial insurance product currently covers expenses arising out of HIV-related illnesses, and that the product being offered would cover all illnesses, not only those related to HIV. It was specified that the proposed product is an individual policy and does not cover other household members.
The survey used two bid structures to measure the WTP for insurance, each containing two to three closed-ended questions followed by an open-ended question in a face-toface interview structure. The annual premiums and payouts were fixed on the basis of the actual rates prevailing under the Star NetPlus Policy. The structure of the bids and the responses are presented as Fig. 1 .
The bids were structured so that if the response to the first level was negative, a question with a lower amount was asked; otherwise, a question with a higher amount was asked. For example, the first question in this section in one version was as follows: 'Do you want to buy health insurance policy for PLHIV that offers coverage for Rs. 30,000 (USD 536) per year at an annual premium of Rs. 1,500 (USD 27)?' Depending on the answer, a subsequent question with a lower or higher bid was asked. These closed-ended questions were then followed by an openended question on maximum WTP per year. There were two versions of the questionnaire, with two different starting bid prices.
The entire section on WTP was asked only if the respondent said he/she would like to join the insurance programme, which was explained in detail. The section was also asked of respondents who were part of an existing insurance programme but were not very satisfied with it.
The rest of the questionnaire included questions designed to elicit information on background details, housing arrangements and asset ownership, information on infection status, ARV and hospitalization.
Study participants were recruited from state networks of HIV-positive people, ART centres, comprehensive care centres (CCCs), non-governmental organizations (NGOs) and Integrated Counseling and Testing Centres (ICTCs). The study was conducted in six states: Andhra Pradesh, Maharashtra, Karnataka, Tamil Nadu, Delhi and Gujarat. Table 1 gives the distribution of the sample in all the states.
Results
Background Characteristics of Respondents
Most of the respondents were married and living with their spouses (56 %). The average age of the group was 35 years, with the lowest being 18 and highest being 68. The majority of the respondents (46.8 %) had completed secondary schooling, i.e. between sixth standard and Secondary School Leaving Certificate (SSLC), and 74 % were currently working. The bulk of those currently not working had never worked (46 %); most of them were women.
Additional details about type of work and other characteristics are given in Table 2 .
More than 78 % of the respondents were on ART. Of those who said they were on ARV, 88 % said that they had never stopped taking ARV drugs. Of the remaining 12 % who did stop, most stopped only once (71 %). About 21 % reported the financial burden of treatment as one reason for stopping (among others).
The most commonly reported diagnosed condition 2 that required inpatient admission was fevers with skin and neurological manifestations (26 %). Diarrhoea, vomiting and other abdominal problems accounted for another 23 %. The third major category included general problems, which include pain, general debility, anaemia and other similar conditions. Some key variables from this survey were compared with the only available data on PLHIV, the National Family Health Survey-3 (NFHS-3), which provided objective estimates of HIV seroprevalence by incorporating anonymous blood testing. While most of the parameters were not strictly comparable because of definitional differences, we looked at education, housing structure and marital status. Those with primary and secondary education as the highest degree accounted for 19 and 39 %, respectively, in NFHS-3. The numbers from the survey were 17 and 46 %, respectively. The percentages of never married PLHIV and currently married PLHIV were also quite comparable (10 and 71 % in the NFHS-3 vs. 9 and 60 % in our sample). Finally, housing structure statistics were also quite comparable.
While some differences are expected in the two samples, overall, these comparisons seem to indicate that the current sample is quite similar to the national sample of HIVpositive individuals, despite the convenience sampling.
Medical Expenditure and Burden of Treatment
The average number of outpatient department (OPD) visits in the sample was between once and three times a year. Approximately 905 respondents had at least one episode of illness for which they had an OPD visit ( Table 3) .
As discussed earlier, more than three-fourths of the respondents who required hospitalization had only one spell of inpatient treatment. The average number of episodes for which the use of inpatient services was required was 1.3. The hospitalization rate from the sample is 225 per 1,000 population, or slightly less than one-fourth of the PLHIV sample.
While 287 respondents required hospitalization, the total reported hospitalization episodes were 369, and details of 361 hospitalizations episode were collected. The average hospitalization expenditure per episode was R6,627 ($US118) per year, with significant variation across states (Table 4) .
For hospitalization, information was collected on expenditure on drugs, diagnostics, hospital admission fees, consultation fees and non-hospital-related expenditure and transportation costs for local and inter-state or inter-district transport where the patient was not local. However, such sub-item details were not available in all cases, and thus the sum of these sub-items can be different from the overall average expense (Table 5) . ART antiretroviral therapy, ARV antiretroviral 2 The term 'diagnosed conditions' was defined as diagnosis for hospitalization in the survey. Therefore, the reported response generally indicates the respondents' perspective of the illness and may not align with exact clinical diagnosis. However, we attempted to classify these responses into medical categories using the 'lay reporting of health information' framework.
Drugs and medicine contributed the most to overall expenditure during hospitalization (34 %), followed by hospital admission fees (21 %) and diagnostic tests (13 %). Average expenditure on non-hospital-related expenses incurred on lodging, food and transportation are comparatively lower. Low average consultation expenses indicate that care was mostly sought in public hospitals (Table 5 ).
An analysis of the spread of expenditure across quartiles based on asset ownership and across states (Table 4) indicates that mean expenditure has a positive relation with economic category. Medical expenditure on hospitalization in the last year in the richest quartile is 1.9 times more than that in the poorest quartile. Mean medical expenditure across states varied greatly from R4,796 ($US86) to R10,526 ($US188) among the six states, indicating that state-specific factors might influence the costs of hospitalization.
When asked about the perception of the burden of treatment, 87 % stated that the burden was high. A majority of respondents (89 %) were not part of any insurance programme; of these, 79 % were willing to join a programme that could reduce their burden. Of those who were part of a coverage scheme, about 40 % said they were 'very satisfied' with the type of coverage.
Demand and Willingness to Pay for Insurance
Of the respondents, 77 % were willing to be part of the proposed insurance scheme. The average WTP per year using the open-ended question was R1,145 ($US20), with a median of R1,000 ($US18), among the 987 respondents who completed the WTP section. A positive relationship between WTP and socioeconomic variables was observed, as described in Table 6 .
The plot of the open-ended question on maximum WTP shows a downward sloping demand curve (Fig. 2) , confirming the negative relationship between price of insurance and demand. When plotted against quartiles (Fig. 3) , it may seem that the WTP does not vary much by quartiles; however, a closer look reveals that at very high prices or premiums there is no demand from the two lower quartiles. Table 7 reports the results based on the ordinary least squares (OLS) regression on the maximum WTP as well as the results of the Weibull estimation using the doublebounded questions. Consistent with earlier literature, the variables included as determinants of WTP were age, education, gender, economic status divided into quartiles, marital status, current work status, total number of household members who are HIV positive, duration on ARVs and whether hospitalized.
The OLS results indicate that the least educated individuals have a lower WTP than those who are most Table 7 . The two means from the OLS and Weibull results are also given in the table, and show that the mean WTP is somewhat higher than the mean of the open-ended WTP per year, at R1,355 ($US24). The Weibull results indicate that only two variables are significant-economic status (the WTP per year of the poorest respondents is significantly lower than those with the highest incomes) and hospitalization.
Both the regression results confirm that those with lower ability to pay have a lower WTP, indicating the robustness of this result.
While the state-level expenditure on hospitalization varies quite a bit, the average WTP based on Weibull estimates do not vary as much across states, indicating that the respondents possibly have a fair idea of the costs of treatment, despite current variations.
Reasons for Unwillingness to Join Insurance Programmes
Slightly less than one-quarter of the sample indicated that they would be unwilling to join the health insurance programme. The most important reason cited for not joining was financial constraints (49.2 %), followed by 'lack of faith/ interest in insurance system' (12.8 %), and further followed by 'lack of decision-making ability' (11.5 %). Only around 1 % cited a breach of privacy and confidentiality as a reason, Proportion of patients Fig. 2 Demand for insurance plotted against price (premium) Fig. 3 Demand for insurance plotted against price (premium) by economic categories. PLHIV people living with HIV and AIDS which clearly indicates that mainstreaming of HIV in the health sector has found its place and this does not seem to be a reason for not availing health coverage facilities ( Table 8 ).
The lack of faith in insurance needs special attention, as this supply side factor can play an important role in expanding health coverage to PLHIV.
Discussion
The main aim of the analysis was to understand if PLHIV would be willing to participate in and purchase commercial health insurance if it was offered to them. The study also attempted to correlate variations in WTP with the socioeconomic characteristics of the respondents. The analysis indicated a high treatment burden on the respondents from hospitalization, which was seen as major concern among the PLHIV. There was a fairly high willingness to join a commercial health insurance programme. The average WTP per year for a premium was R1,145-1,355 or $US20- 24 . While the open-ended results indicate that more variables may determine the WTP, the Weibull results showed that only economic status and hospitalization were important determinants of respondents' WTP. The mean WTP per year is about one-fifth of the mean expenditure on hospitalization (R6,627), indicating a rational decision-making process by respondents who are willing to pay a reasonable premium annually to avoid possible health costs subsequently.
These results need to be interpreted in the context of the current government policy to exclude all conditions related to HIV, pre-existing or otherwise. The findings indicate that among PLHIV, insurance is a normal good with a negative relationship with price and an average WTP that is not too low. However, the ability to pay might constrain demand from the lower economic categories. This can serve as evidence for possible subsidies to economically vulnerable populations. In fact, the Government is already paying the premium of an existing national health insurance scheme for the BPL population. The scheme-the Rashtriya Swasthya Bima Yojana (RSBY)-has low premiums of R750 or $US14, which are paid by the Government; only a registration fee is paid by the beneficiary. While HIV was excluded to begin with, it was subsequently removed from the list of conditions that are permanently excluded [21] . However, despite the directive to remove HIV from the list of exclusions, awareness about this seems to be lacking both at the state level and among the PLHIV community [22] , and it is not clear that PLHIV may be beneficiaries under this scheme. While there are issues of identification of poor as well as sub-optimal enrolment under RSBY, the scheme has reached 119 million beneficiaries [23] . No statistics exist to indicate how many PLHIV also have a BPL card; additional steps can be taken to ensure that all PLHIV who are of poor economic status are eligible and able to purchase insurance, so that subsidies also reach them. Using RSBY as an instrument for extending insurance to PLHIV has been also advocated by others [24] .
Other approaches-like according BPL status to PLHIV to enable them to benefit from the Government-sponsored health coverage scheme-exist in the country [25] . Additionally, many states have been providing insurance for PLHIV through different mechanisms. In addition to some small-scale pilot projects initiated by NGOs with donor funding (Freedom Foundation and Karuna Trust), there have been larger state-wide schemes like Aarogyasri (Andhra Pradesh) and Yeshasvini (Karnataka) that do not exclude PLHIV if they also are BPL.
Despite these various initiatives, the main private and national health insurance companies (24 life and 27 nonlife insurers) continue to exclude PLHIV from accessing these products. It is a logical next step for the Insurance Regulatory and Development Authority (IRDA) to remove the exclusion clause, so that any PLHIV-irrespective of their economic status-can purchase commercial insurance, if they so desire, since most of them are willing and able to pay a premium. The insurance industry may be concerned about the potential lowering of profits in case they do enrol PLHIV; however, recent evidence exists to show that if permanent and pre-existing clauses are removed, the additional burden on insurance companies would be very modest due to the fairly low rates of hospitalization in the current scenario of ARV drugs. The results of this paper can be used as further evidence to trigger such changes in policies. In any case, separate insurance products for PLHIV (or any other group) like the Star Health insurance violates the very principle on which insurance is based, and cannot be the preferred option. While some recent high-level advocacy and dialogue among stakeholders like the IRDA, the National AIDS Control Programme (under the Ministry of Health and Family Welfare) and the insurance sector has resulted in some initial directives from the IRDA towards inclusion, operationally, the insurance sector is yet to initiate processes that would result in India joining the group of countries that do not exclude HIV from health insurance products.
The study can be improved upon by expanding the sample size, which might reduce some of the biases resulting from convenience sampling. Also, while the sample was drawn from state-level networks of positive people and ART centres, it is possible that their characteristics differ in significant ways from other PLHIV who are not part of the network. A subsequent survey could also attempt to reach out to other PLHIV who are outside of the network to make the results more robust. A third improvement would be to have more iteration with the initial bids to get a wider range of prices, again possible with a larger sample.
Conclusion
The significant burden of treatment on PLHIV and their WTP for health insurance is evidence of need as well as demand; therefore, continuing to exclude them from commercial health insurance products seems both unjust and unnecessary. These results can serve as evidence to trigger policy changes in the health insurance sector in India, so that India can join the list of countries that have taken a more rational approach towards inclusion, rather than exclusion, in their health insurance policies.
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Appendix : Equation for Regression
Log (max WTP) = f(age, age squared, whether female, whether currently working, education up to primary, education up to secondary, whether currently married, duration 
